FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer

European Journal of Cancer

Volumn 51, Issue 10, 2015, Pages 1243-1252

  Bokemeyer, C ^a   Kohne C H ^b   Ciardiello, F ^c   Lenz, H J ^d   Heinemann, V ^e   Klinkhardt, U ^f   Beier, F ^f   Duecker, K ^f   Van Krieken, J H ^g   Tejpar, S ^h  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b KLINIKUM OLDENBURG   (Germany)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^f MERCK KGAA   (Germany)

^g RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^h UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Cetuximab; FOLFOX4; KRAS; NRAS; OPUS; RAS

Indexed keywords

CETUXIMAB; FLUOROURACIL; FOLINIC ACID; GENOMIC DNA; K RAS PROTEIN; OXALIPLATIN; ANTINEOPLASTIC AGENT; CODON; MONOCLONAL ANTIBODY; PLATINUM COMPLEX;

ADD ON THERAPY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CODON; COLORECTAL CANCER; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; EXON; GENE MUTATION; HUMAN; MUTANT; NEXT GENERATION SEQUENCING; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; POPULATION SIZE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROPORTIONAL HAZARDS MODEL; PYROSEQUENCING; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; WILD TYPE; CLINICAL TRIAL; COLORECTAL NEOPLASMS; DISEASE FREE SURVIVAL; GENETICS; MUTATION; ONCOGENE RAS; PATHOLOGY;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CODON; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; EXONS; FLUOROURACIL; GENES, RAS; HUMANS; LEUCOVORIN; MUTATION; ORGANOPLATINUM COMPOUNDS;

EID: 84930047088     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2015.04.007     Document Type: Article

References (19)

1. C. Bokemeyer, I. Bondarenko, and A. Makhson Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer J Clin Oncol 27 2009 663 671
2. C. Bokemeyer, I. Bondarenko, and J.T. Hartmann Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study Ann Oncol 22 2011 1535 1546
3. J.Y. Douillard, S. Siena, and J. Cassidy Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study J Clin Oncol 28 2010 4697 4705
4. S.A. Forbes, N. Bindal, and S. Bamford COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer Nucleic Acids Res 39 2011 D945 D950
5. M.J. Sorich, M.D. Wiese, and A. Rowland Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials Ann Oncol 2014
6. J.Y. Douillard, K.S. Oliner, and S. Siena Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer N Engl J Med 369 2013 1023 1034
7. C.Y. Chen, S.C. Shiesh, and S.J. Wu Rapid detection of K-ras mutations in bile by peptide nucleic acid-mediated PCR clamping and melting curve analysis: comparison with restriction fragment length polymorphism analysis Clin Chem 50 2004 481 489
8. D. Dressman, H. Yan, and G. Traverso Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations Proc Natl Acad Sci U S A 100 2003 8817 8822
9. F. Diehl, M. Li, and D. Dressman Detection and quantification of mutations in the plasma of patients with colorectal tumors Proc Natl Acad Sci U S A 102 2005 16368 16373
10. F. Diehl, K. Schmidt, and K.H. Durkee Analysis of mutations in DNA isolated from plasma and stool of colorectal cancer patients Gastroenterology 135 2008 489 498
11. E.L. Kaplan, and P. Meier Nonparametric estimation from incomplete observations J Am Stat Assoc 53 1958 457 481
12. H. Lenz, D. Niedzwiecki, and F. Innocenti CALGB/SWOG 80405: Phase III trial of FOLFIRI or mFOLFOX6 with bevacizumab or cetuximab for patients with expanded RAS analyses in untreated metastatic adenocarcinoma of the colon or rectum ESMO 2014
13. V. Heinemann, L.F. von Weikersthal, and T. Decker FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial Lancet Oncol 15 2014 1065 1075
14. L.S. Schwartzberg, F. Rivera, and M. Karthaus PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer J Clin Oncol 32 2014 2240 2247
15. E. Van Cutsem, H.J. Lenz, and C.H. Kohne Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer J Clin Oncol 33 2015 692 700
16. B.L. Parsons, and M.B. Myers Personalized cancer treatment and the myth of KRAS wild-type colon tumors Discov Med 15 2013 259 267
17. P. Laurent-Puig, D. Pekin, and C. Normand Clinical relevance of KRAS-mutated sub-clones detected with picodroplet digital PCR in advanced colorectal cancer treated with anti-EGFR therapy Clin Cancer Res 2014
18. D. Tougeron, T. Lecomte, and J.C. Pages Effect of low-frequency KRAS mutations on the response to anti-EGFR therapy in metastatic colorectal cancer Ann Oncol 24 2013 1267 1273
19. Taly V, Laurent-Puig, P., Pekin, D., Doe J. Clinical significance of low frequency KRAS and BRAF subclones for advanced colon cancer management. American Association for Cancer Research Annual Meeting San Diego, CA, April 5-9, 2014: Abstr 2820.